RxDoctor Payments Data

Vinita Patel, DO

Rheumatology · Bronx, NYNPI 1154594646

Payments from drug & device makers

$73,018in general payments, 2019–2025

Across 566 payments — averaging $129.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$28K
  • AbbVie$24K
  • Bristol Myers Squibb$14K
  • UCB, Inc.$1K
  • Novartis$1K
  • Johnson & Johnson$1K
  • plus $3K from 11 others

What the payments were for

  • Consulting fees$5,8138%
  • Speaking & faculty fees$46,07163%
  • Travel & lodging$1,6252%
  • Food & beverage$19,00426%
  • Education$5061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,018 in reported general payments places this provider in the 80th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$323,066
Medicare patients
323
Services billed
15,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$214,843
Teriparatide16$63,123
RayosPrednisone14$54,518
ProliaDenosumab31$53,382
ActemraTocilizumab11$26,359
Febuxostat57$7,777
Hydroxychloroquine Sulfate134$3,332
Leflunomide37$2,709
Colchicine48$2,563
MethotrexateMethotrexate Sodium126$2,278
Prednisone334$2,271
Pilocarpine Hcl17$1,099
Risedronate Sodium13$1,072
Celecoxib50$987
Alendronate Sodium137$985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenRayos, Prolia$28,271$107,90045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 541 rheumatology providers in New York.

Other rheumatology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →